Home : Unsafe Drugs : Remicade
Remicade
Remicade (Infliximab) is an immunosuppresant, approved by the FDA for the treatment of Crohn's Disease, rheumatoid arthritis, and juvenile arthritis. It is administered through a subcutaneous injection.
The most common side effects of Remicade are dry cough, fever, weight loss, fever with chills, body aches, flu symptoms. Patients taking Remicade are at increased risk for serious adverse effects, including serious infections that can lead to hospitalization or death. Because Remicade affects the immune system, it can lower the body's ability to fight infections, such as tuberculosis and other opportunistic infections. Remicade is a blocker of TNF (tumor necrosis factor) and may cause lymphomas (a form of cancer) and other malignancies.
Recently, Remicade was given a Black Box Label Warning by the FDA. The Black Box Warning is the strongest warning label a drug can have applied to it. Drugs that carry a high risk of serious side effects or potentially deadly adverse reactions are given this warning. This label is given only after medical studies have indicated that there are serious risks associated with the side effects of the medication.
Fast Facts
| Name: | Remicade |
| Generic: | Infliximab |
| Manufacturer: | Johnson & Johnson |
| Date approved: | 1999 |
| Status: | Prescription Only - Black Box Warning Label |
| Approved uses: | Psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, sarcoidosis and ulcerative colitis |
| Off-Label uses: | None |
| Side effects: | Low or high blood pressure, chest pain, difficulty breathing, rash, itching, fever and chills. Serious Fungal Infections have have been reported by the FDA, giving it a Black Box Warning label. |
| Related topics: | Cimzia, Humira, Enbrel |
FDA Announces Black Box Label Warning for Remicade
In early September, 2008, the FDA announced it would require stronger warnings for four medications commonly used in the treatment of rheumatoid arthritis. The warning label is known as the... read more
View the Remicade Main Articles page here
FDA Information Related to Remicade
October 2006 Monthly Safety Labeling
August 2006 Safety Labeling Changes
View the Remicade FDA Information page here
MSN Newsfeeds Related to Remicade
Pharma Sector: Few Newsmakers Of The Week - Pfizer, Opexa, Onyx ...
Data showing improvement in spinal mobility, spinal inflammation
View the Remicade MSN Newsfeeds page here
News Articles Related to Remicade
Treatment and Health News (Orphan Disease Portal)
View the Remicade News Articles page here
Wikipedia Entries Related to Remicade
View the Remicade Wikipedia Entries page here
Books Related to Remicade
View the Remicade Books page here






